July 15 (Reuters) - Ziopharm Oncology Inc said a
brain cancer patient died of cranial bleeding about two weeks
after starting treatment with the gene therapy developer's lead
experimental drug, sending its stock down as much as 16 percent
on Friday.
Read more
No comments:
Post a Comment